share_log

Maxim Group Initiates Coverage On Alzamend Neuro With Buy Rating, Announces Price Target of $1.5

Benzinga ·  Apr 12, 2023 09:31

Maxim Group analyst Michael Okunewitch initiates coverage on Alzamend Neuro (NASDAQ:ALZN) with a Buy rating and announces Price Target of $1.5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment